Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

NCT07400523 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

446

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Ribociclib plus aromatase inhibitor
DRUG: Aromatase inhibitor

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University